Email this article 
Prevention of urinary tract infections after gynecological and oncogynecological surgeries
- Authors: Kedrova A.G.1, Berishvili A.I.2, Gerasimov A.V.1, Greyan T.A.1,2, Zaytseva O.V.1, Denisova N.S.1
-
Affiliations:
- Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of Russia
- Academy of Postgraduate Education, Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of Russia
- Issue: Vol 21, No 3 (2025)
- Pages: 131-136
- Section: GYNECOLOGY. ORIGINAL REPORTS
- Published: 21.11.2025
- URL: https://ojrs.abvpress.ru/ojrs/article/view/1409
- DOI: https://doi.org/10.17650/1994-4098-2025-21-3-131-136
- ID: 1409
Cite item
Full Text
Abstract
Aim. To evaluate the efficacy of the dietary supplement NefroBest-N® for the prevention of urinary tract infections and inflammation after gynecological and oncogynecological surgeries.
Materials and methods. The observational study included two groups of patients. The study group included 72 patients who received therapy containing the herbal preparation NefroBest-N®, 1 capsule twice daily for 30 days following surgery.
The control group included 60 patients who did not receive phytoprophylaxis postoperatively. Antibiotic prophylaxis for all patients was administered with cefazolin 1 g intravenously 1 hour before surgery. Patients also underwent a standard preoperative examination, including a blood biochemistry panel (urea, creatinine, potassium, sodium, C-reactive protein), a urinalysis (presence of mucus, white blood cell count), and a urine culture.
Results. Postoperative leukocyturia was more often observed in the control group – 23.3 % of cases versus 8.3 % of cases in the main group. Extended antibiotic therapy was also more common in the control group. According to the questionnaire, patients receiving NefroBest-N® scored better on their general condition than the control group (16 points versus 12 points), as well as they had less pronounced dysuric symptoms (21 points versus 29 points, respectively) and pain (12 points versus 18 points, respectively).
Conclusion. The use of the herbal preparation NefroBest-N® in the postoperative period reduces the risk of developing leukocyturia and dysuric symptoms, improving the overall well-being of patients.
Keywords
About the authors
A. G. Kedrova
Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of Russia
Author for correspondence.
Email: kedrova.anna@gmail.com
ORCID iD: 0000-0003-1031-9376
Anna Genrikhovna Kedrova
28 Orekhovyy Bulvar, Moscow 115682
Russian FederationA. I. Berishvili
Academy of Postgraduate Education, Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of Russia
ORCID iD: 0000-0002-0565-3997
91 Volokolamskoe Shosse, Moscow 125371
Russian FederationA. V. Gerasimov
Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of Russia
28 Orekhovyy Bulvar, Moscow 115682
Russian FederationT. A. Greyan
Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of Russia; Academy of Postgraduate Education, Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of Russia
ORCID iD: 0000-0003-4118-3002
28 Orekhovyy Bulvar, Moscow 115682
91 Volokolamskoe Shosse, Moscow 125371
Russian FederationO. V. Zaytseva
Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of Russia
28 Orekhovyy Bulvar, Moscow 115682
Russian FederationN. S. Denisova
Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of Russia
28 Orekhovyy Bulvar, Moscow 115682
Russian FederationReferences
- Urology. Russian Clinical Guidelines. Eds.: Yu.G. Alyaev, P.V. Glybochko, D.Yu. Pushkar. Moscow, 2017. 544 p. (In Russ.).
- Taliento C., Scutiero G., Milano C. et al. Surgical site infections and sepsis in gynecological surgery. Int J Gynecol Obstet 2025;1–12. doi: 10.1002/ijgo.70356
- Ban K.A., Minei J.P., Laronga C. et al. American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. J Am Coll Surg 2017;224(1):59–74. doi: 10.1016/j.jamcollsurg.2016.10.029
- Mercadel A.J., Holloway S.B., Saripella M., Lea J.S. Risk factors for catheter-associated urinary tract infections following radical hysterectomy for cervical cancer. Am J Obstet Gynecol 2023;228(6):718.e1–7. doi: 10.1016/j.ajog.2023.02.019
- Wagenlehner F.M., Abramov-Sammariva D., Holler M. et al. Non-antibiotic herbal therapy (BNO 1045) versus antibiotic therapy (Fosfomycin trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre, non-inferiority phase III trial. Urol Int 2018;101:327–36. doi: 10.1159/000493368
- Kononova I.N., Kuzina T.V., Oparina O.S. Optimization of therapy for pregnant women with asymptomatic bacteriuria. Rossiyskiy vestnik akushera-ginekologa = Russian Bulletin of ObstetricianGynecologist 2020;20(5):97–102. (In Russ.). doi: 10.17116/rosakush20202005197
- Neymark A.I., Razdorskaya M.V., Neymark B.A., Nozdrachev N.A. Treatment and prevention of chronic cystitis in women. Urologiya = Urology 2021;(2):51–6. (In Russ.). doi: 10.18565/urology.2021.2.51-56
- Kotov S.V., Nizin P.Yu. Possibilities of non-antibacterial therapy and prevention of urinary tract infections. Eksperimentalnaya i klinicheskaya urologiya = Experimental and Clinical Urology 2023;16(3):105–10. (In Russ.). doi: 10.29188/2222-8543-2023-16-3-105-110
- Berdichevskiy V.B., Zhmurov V.A., Sapozhenkova E.V. et al. Physiology of non-diabetic glucosuria and its role in the recurrence of urinary tract infections: correction methods. Klinicheskaya nefrologiya = Clinical Nephrology 2022;14(2):47–50. (In Russ.). doi: 10.18565/nephrology.2022.2.47-50
- Kolpatsinidi F.G., Sergeev V.P., Kyzlasov P.S. et al. Experience with the use of NefroBest-N for the rehabilitation of patients who underwent radical laparoscopic cystectomy. Urologiya = Urology 2023;(4):62–8. (In Russ.). doi: 10.18565/urology.2023.4.62-68
Supplementary files
